Strata Critical Medical Announces Second Quarter 2026 Results
Strata Critical Medical reported Q2 2026 revenue of $72.5 million, a 60.7% increase year-over-year, driven by growth in both Logistics and Clinical segments. Adjusted EBITDA rose 219.8% to $7.9 million with a margin of 10.9%, while free cash flow reached $2.9 million.
Key figures
- Eps
- (0.12)
- Revenue
- $72.5 million
- Guidance
- Revenue of $285-295 million (previously: $260-275 million); Adjusted EBITDA of $33-35 million (previously: $29-33 million)
- Revenue Yoy
- 60.7%
- Fcf
- $2.9 million
- Net loss
- $(10.5) million
- Adjusted ebitda
- $7.9 million
- Clinical revenue
- $24.3 million
- Logistics revenue
- $48.2 million
- Operating cash flow
- $5.7 million
- Adjusted ebitda margin
- 10.9%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.